Free Trial

Acasti Pharma Q3 2023 Earnings Report

Acasti Pharma EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Acasti Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acasti Pharma Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Acasti Pharma Earnings Headlines

Buy this coin BEFORE Inauguration Day …
Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.
Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)
See More Acasti Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acasti Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acasti Pharma and other key companies, straight to your email.

About Acasti Pharma

Acasti Pharma (NASDAQ:ACST) engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

View Acasti Pharma Profile

More Earnings Resources from MarketBeat